For instance, the pathological grade, tumor size, clinical stage determined by imaging techniques, pre-treatment levels of the carcinoembryonic antigen (CEA), nCRT and surgery intervals, and tumor budding, among others, may impact the nCRT response (1, 9–11). The gene discussed is CEACAM5; the disease is neoplasm.